RT Journal Article
SR Electronic
T1 Identification of COVID-19 Subtypes Based on Immunogenomic Profiling
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.24.21250387
DO 10.1101/2021.01.24.21250387
A1 Feng, Qiushi
A1 Wang, Xiaosheng
YR 2021
UL http://medrxiv.org/content/early/2021/01/26/2021.01.24.21250387.abstract
AB Although previous studies have shown that the host immune response is crucial in determining clinical outcomes in COVID-19 patients, the association between host immune signatures and COVID-19 patient outcomes remains unclear. Based on the enrichment levels of 11 immune signatures (eight immune-inciting and three immune-inhibiting signatures) in leukocytes of 100 COVID-19 patients, we identified three COVID-19 subtypes: Im-C1, Im-C2, and Im-C3, by clustering analysis. Im-C1 had the lowest immune-inciting signatures and high immune-inhibiting signatures. Im-C2 had medium immune-inciting signatures and high immune-inhibiting signatures. Im-C3 had the highest immune-inciting signatures while the lowest immune-inhibiting signatures. Im-C3 and Im-C1 displayed the best and worst clinical outcomes, respectively, suggesting that antiviral immune responses alleviated the severity of COVID-19 patients. We further demonstrated that the adaptive immune response had a stronger impact on COVID-19 outcomes than the innate immune response. The patients in Im-C3 were younger than those in Im-C1, indicating that younger persons have stronger antiviral immune responses than older persons. Nevertheless, we did not observe a significant association between sex and immune responses in COVID-19 patients. In addition, we found that the type II IFN response signature was an adverse prognostic factor for COVID-19. Our identification of COVID-19 immune subtypes has potential clinical implications for the management of COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the China Pharmaceutical University (grant number 3150120001 to XW).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIn this study, using a publicly available RNA-Seq gene expression profiles in 100 leukocyte samples from COVID-19 patients GEO (https://www.ncbi.nlm.nih.gov/geo/) HLAHuman leukocyte antigenTfhT follicular helper cellsTh1 cellsType 1 T helper cellsTh2 cellsType 2 T helper cellsNKNatural killerpDCsPlasmacytoid dendritic cellsTregRegulatory T cellsICUIntensive care unitMVSMechanical ventilatory supportHFDHospital-free days at day 45WGCNAWeighted gene co-expression network analysisFDRFalse discovery rateRFRandom forest